Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma: a case report
Open Access
- 10 November 2018
- journal article
- case report
- Published by Springer Nature in BMC Neurology
- Vol. 18 (1) , 1-5
Abstract
Paraneoplastic neurological syndromes (PNS) are rare disorders associated with cancer and are believed to be immune mediated. Patients with autonomic PNS suffer from variable combinations of parasympathetic and sympathetic failure. Autonomic PNS are usually associated with other PNS, such as encephalomyelitis and sensory neuropathy; however, autonomic symptoms may rarely manifest as PNS symptoms. Autonomic symptoms, therefore, may be overlooked in patients with cancer. We described a 65-year-old Japanese man who was diagnosed with autonomic PNS due to small-cell lung carcinoma (SCLC) with Eastern Cooperative Oncology Group (ECOG) performance status 3, who suffered from orthostatic hypotension, and urinary retention needing a urethral balloon. Laboratory studies showed decreased levels of noradrenaline, and were positive for anti-ganglionic acetylcholine receptor antibody, type 1 antineuronal nuclear antibody, and sry-like high mobility group box 1 antibody. Nerve conduction evaluations and 123I-metaiodobenzylguanidine myocardial scintigraphy showed no abnormalities. Abdominal contrast-enhanced computed tomography revealed marked colonic distention. The patient’s autonomic symptoms resolved following integrated treatment (symptomatic treatment, immunotherapy, and additional chemotherapy) enabling the patient to walk, remove the urethral balloon, and endure further chemotherapy. ECOG performance status remained at 1, 10 months after admission. Integrated treatment for autonomic PNS may improve autonomic symptoms and ECOG performance status of patients with cancer.Keywords
This publication has 17 references indexed in Scilit:
- Therapy of paraneoplastic disorders of the CNSExpert Review of Neurotherapeutics, 2015
- SOX1 antibodies in sera from patients with paraneoplastic neurological syndromesActa Neurologica Scandinavica, 2011
- Ganglionic Acetylcholine Receptor AutoantibodyArchives of Neurology, 2009
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndromeNeurology, 2008
- Autoimmune and Paraneoplastic ChannelopathiesNeurotherapeutics, 2007
- Autonomic paraneoplastic neurological syndromesAutoimmunity Reviews, 2007
- Recommended diagnostic criteria for paraneoplastic neurological syndromesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic NeuropathiesNew England Journal of Medicine, 2000
- Immunological and endocrinological abnormalities in paraneoplastic disorders with involvement of the autonomic nervous systemThe Italian Journal of Neurological Sciences, 1997